SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-049994
Filing Date
2024-12-13
Accepted
2024-12-13 16:10:25
Documents
15
Period of Report
2024-12-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 42343
2 ex10-1.htm EX-10.1 40740
  Complete submission text file 0001493152-24-049994.txt   271521

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE kapa-20241210.xsd EX-101.SCH 3027
4 XBRL LABEL FILE kapa-20241210_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE kapa-20241210_pre.xml EX-101.PRE 24173
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3801
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

IRS No.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42275 | Film No.: 241548429
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)